Antithrombotic effect of a new nitric oxide donor (LA419) on experimental thrombogenesis

European Journal of Clinical Investigation

Volumn 35, Issue 5, 2005, Pages 337-342

  Hernandez, M R ^a   Tonda, R ^a   Arderiu, G ^a   Pino, M ^a   Serradell, M ^a   Escolar, G ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

Author keywords

NO donors; Perfusion models; Platelet interaction

Indexed keywords

ANTICOAGULANT AGENT; COLLAGEN; LA 419; NITRIC OXIDE DONOR; UNCLASSIFIED DRUG;

ARTICLE; CARDIOVASCULAR DISEASE; CELL INTERACTION; CONTROLLED STUDY; EX VIVO STUDY; EXPERIMENTAL MODEL; HUMAN; HUMAN CELL; MORPHOMETRICS; PRIORITY JOURNAL; SURFACE PROPERTY; THROMBOCYTE ADHESION; THROMBOCYTE FUNCTION; THROMBOSIS; TISSUE PERFUSION; VASODILATATION;

ANIMALS; BLOOD PLATELETS; COLLAGEN; FIBRINOLYTIC AGENTS; HORSES; HUMANS; ISOSORBIDE DINITRATE; MODELS, BIOLOGICAL; NITRIC OXIDE DONORS; PLATELET ACTIVATION; PLATELET ADHESIVENESS; RABBITS; THROMBOSIS;

EID: 18744368154     PISSN: 00142972     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2362.2005.01496.x     Document Type: Article

References (36)

1. Pyatakova NV, Khropov YV, Churakov AM, Tarasova NI, Serezhenkov VA, Vanin AF et al. Derivatives of bezotetrazine-1,3-dioxide are new NO-donors, activators of soluble guanylate cyclase, and inhibitors of platelet aggregation. Biochem 2002;67:329-34.
2. Stamler J, Mendelsohn ME, Amarante P, Smick D, Andon N, Davies PF et al. N-Acetylcysteine potentiates platelet inhibition by endothelium-derived relaxing factor. Circ Res 1989;65:789-95.
3. Cooke JP, Stamler J, Andon N, Davies PF, McKinley G, Loscalzo J. Flow stimulates endothelial cells to release a nitrovasodilator that is potentiated by reduced thiol. Am J Physiol 1990;259:H804-12.
4. Keh D, Gerlach M, Kürer I, Seiler S, Kerner T, Falke KJ et al. The effects of nitric oxide (NO) on platelet membrane receptor expression during activation with human thrombin. Blood Coagul Fibrinolysis 1996;7:615-24.
5. Michelson AD, Benoit SE, Furman MI, Breckwoldt WL, Rohrer MJ, Barnard MR et al. Effects of nitric oxide/EDRF on platelet surface glycoproteins. Am J Physiol 1996;270:H1640-8.
6. Abrams J. Beneficial actions of nitrates in cardiovascular disease. Am J Cardiol 1996;77:31C-7C.
7. Aarts PAMM, Heethaar RM, Sixma JJ. Red blood cell deformability influences platelet-vessel wall interaction in flowing blood. Blood 1984;64:1228-33.
8. Korbut R, Grylewski RJ. Nitric oxide from polymorphonuclear leukocytes modulates red blood cell deformability in vitro. Eur J Pharmacol 1993;234:17-22.
9. Failli P, Cecchi E, Tosti-Guerra C, Mugelli A, Laffi G, Zilletti L et al. Effect of some cyclooxygenase inhibitors on the increase in guanosyne 3′:5′-cyclic monophosphate induced by NO-donors in human whole platelets. Br J Pharmacol 1998;123:1457-63.
10. De Graaf JC, Banga JD, Moncada S, Palmer MRJ, de Groot PG, Sixma JJ. Nitric oxide functions as an inhibitor of platelet adhesion under flow conditions. Circulation 1992;85:2284-90.
11. Bozzo J, Hernandez MR, Galan AM, Heras M, Ordinas A, Escolar G. Antiplatelet effects of sodium nitroprusside in flowing human blood: Studies under normoxic and hypoxic conditions. Thromb Res 2000;97:217-25.
12. Sakariassen KS, Aarts PA, de Groot PG, Houdijk WP, Sixma JJ. A perfusion chamber developed to investigate platelet interaction in flowing blood with human vessel wall cells, their extracellular matrix, and purified components. J Lab Clin Med 1983;102:522-35.
13. Baumgartner HR. Platelet interaction with collagen fibrils in flowing blood. I. Reaction of human platelets with alpha chymotrypsin digested subendothelium. Thromb Haemost 1977;37:1-16.
14. Bossavy JP, Sakariassen KS, Barret A, Boneu B, Cadroy Y. A new method for quantifying platelet deposition in flowing native blood in an ex vivo model of human thrombogenesis. Thromb Haemost 1998;79:162-8.
15. Escolar G, Bastida E, Castillo R, Ordinas A. Development of a Computer program to analyze the parameters of platelet vessel wall interaction. Haemostasis 1986;16:8-14.
16. Escolar G, Bastida E, Castillo R, Ordinas A. Ticlopidine inhibits platelet thrombus formation studied in a flowing system. Thromb Res 1987;45:561-71.
17. Baumgartner HR. Effects of acetylsalicylic acid, sulfinpyrazone and dipyridamole on platelet adhesion and aggregation in flowing native and anticoagulated blood. Haemostasis 1979;8:340-52.
18. International patent number WO 00/20420. Intellectual property world organization. Derivatives of isosorbide mononitrate as vasodilator agents with reduced tolerance.
19. Freedman JE, Loscalzo J, Barnard M, Alpert C, Keaney Jr JF, Michelson AD. Nitric oxide released from activated platelets inhibits platelet recruitment. J Clin Invest 1997;100:350-6.
20. Furlong B, Henderson AH, Lewis MJ, Smith JA. Endothelium-derived relaxing factor inhibits in vitro platelet aggregation. Br J Pharmacol 1987;90:687-92.
21. Radomsky MW, Palmer RMJ, Moncada S. The role of nitric oxide and cGMP in platelet adhesion to subendothelium. Biochem Biophys Res Commun 1987;148:1482-9.
22. Vilahur G, Segales E, Salas E, Badimon L. Effects of a novel platelet nitric oxide donor (LA816), aspirin, clopidogrel, and combined therapy in inhibiting flow- and lesion-dependent thrombosis in the porcine ex vivo model. Circulation 2004;110:1686-93.
23. Anderson RA, Ellis GR, Chirkov YY, Holmes AS, Payne N, Blackman DJ et al. Determinants of platelet responsiveness to nitric oxide in patients with chronic heart failure. Eur J Heart Fail 2004;6:47-54.
24. Sase K, Michel T. Expression of constitutive endothelial nitric oxide synthase in human blood platelets. Life Sci 1995;57:2049-55.
25. Radomski MW, Palmer RMJ, Moncada S. An 1-arginine/nitric oxide pathway present in human platelets regulates aggregation. Proc Natl Acad Sci USA 1990;87:5193-7.
26. Yoshimoto H, Suehiro A, Kakishita E. Exogenous nitric oxide inhibits platelet activation in whole blood. J Cardiovasc Pharmacol 1999;33:109-15.
27. Maree AO, Cox D. Thrombosis and nitric oxide donor drugs. Thromb Haemost 2004;91:848-50.
28. Roux S, Tschopp T, Baumgartner HR. Effects of napsagatran (Ro 46-6240), a new synthetic thrombin inhibitor and of heparin in a canine model of coronary artery thrombosis: comparison with an ex vivo annular perfusion chamber model. J Pharmacol Exp Ther 1996;277:71-8.
29. Inauen W, Bombeli T, Baumgartner HR, Haeberli A, Straub PW. Effects of the oral anticoagulant phenprocoumon on blood coagulation and thrombogenesis induced by rabbit aorta subendothelium exposed to flowing human blood, role of dose and shear rate. J Lab Clin Med 1991;118:280-8.
30. Vilahur G, Segalés E, Casaní L, Badimon L. A novel anti-ischemic nitric oxide donor inhibits thrombosis without modifying hemodynamic parameters. Thromb Haemost 2004;91:1035-43.
31. Alemany M, Hernandez MR, Bozzo J, Bono A, Escolar G, Ordinas A et al. A deleterious effect of aspirin on the antithrombotic properties of endothelial cells is not observed with platelets previously exposed to aspirin: studies in a flow system. Platelets 1996;7:29-34.
32. Bozzo J, Hernández MR, Alemany M, Rosell G, Bastida E, Escolar G et al. Effects of aspirin and indomethacin separately in red blood cells and platelets. Modulation of the adhesive and cohesive functions of platelets under flow conditions. Platelets 1996;7:277-82.
33. Bozzo J, Escolar G, Hernandez MR, Galan AM, Ordinas A. Prohemorrhagicpotential of dipyrone, ibuprofen, ketorolac and aspirin: mechanisms associated with blood flow and erythrocyte deformability. J Cardiovasc Pharmacol 2001;38:183-90.
34. Hernández MR, Tonda R, Pino M, Serradell M, Arderiu G, Escolar G. Evaluation of effects of rofecoxib on platelet function in an in vitro model of thrombosis with circulating human blood. Eur J Clin Invest 2004;34:297-302.
35. Bozzo J, Hernández MR, Ordinas A. Reduced red cell deformability associated with blood flow and platelet activation: improved by dipyridamole alone or combined with aspirin. Cardiovasc Res 1995;30:725-30.
36. Bozzo J, Hernández MR, Ordinas A. Los eritrocitos modulan el efecto antiagregante de la aspirina y el dipiridamol: Estudio bajo condiciones de flujo. Sangre 1996;41:13-8.